Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor Kelly RJ; Rixe OTarget Oncol 2009[Dec]; 4 (4): 297-305An improved understanding of the molecular biology involved in many solid tumors has led to the development of novel targeted agents. Axitinib is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1, 2, and 3. This review presents preclinical and clinical data available for axitinib, including findings from key phase II clinical trials in a wide variety of tumors including melanomas and renal, pancreatic, thyroid, breast, lung, and colorectal carcinomas. The differences between axitinib and other VEGFR inhibitors are explored and details of the possible use of blood pressure elevation and erythropoietin blood levels as predictive markers of VEGF/VEGFR pathway inhibition are outlined. Ongoing Phase III studies in pancreatic and metastatic renal cell carcinoma should help to determine the optimum utilization of these agents at the appropriate stage of disease.|*Drug Delivery Systems[MESH]|Angiogenesis Inhibitors/*administration & dosage/therapeutic use[MESH]|Animals[MESH]|Antineoplastic Agents/therapeutic use[MESH]|Axitinib[MESH]|Disease Models, Animal[MESH]|Imidazoles/*administration & dosage/therapeutic use[MESH]|Indazoles/*administration & dosage/therapeutic use[MESH]|Lung Neoplasms/*drug therapy[MESH]|Mice[MESH]|Mice, Nude[MESH]|Neoplasm Transplantation[MESH]|Neovascularization, Pathologic/*drug therapy[MESH]|Receptors, Vascular Endothelial Growth Factor/*antagonists & inhibitors[MESH]|Signal Transduction[MESH]|Vascular Endothelial Growth Factor A/*administration & dosage/antagonists & inhibitors[MESH]|Xenograft Model Antitumor Assays[MESH] |